<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37170865</PMID><DateCompleted><Year>2023</Year><Month>05</Month><Day>18</Day></DateCompleted><DateRevised><Year>2023</Year><Month>05</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1756-8927</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>8</Issue><PubDate><Year>2023</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Future medicinal chemistry</Title><ISOAbbreviation>Future Med Chem</ISOAbbreviation></Journal><ArticleTitle>Levamisole derivatives as immune modulators for the treatment of amyotrophic lateral sclerosis (ALS).</ArticleTitle><Pagination><StartPage>651</StartPage><EndPage>659</EndPage><MedlinePgn>651-659</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.4155/fmc-2023-0028</ELocationID><Abstract><AbstractText><b>Aim:</b> To discover derivatives of the anthelmintic drug levamisole, which has been reported to possess immune-modulatory properties, as treatments for amyotrophic lateral sclerosis (ALS), which has been suggested to be in part an autoimmune disease. <b>Results:</b> We have synthesized ten analogs of the racemic version of levamisole, tetramisole, as well as eleven&#xa0;analogs on a related system. All of the analogs have been tested for their ability to affect the response of five ALS-relevant cytokines. <b>Conclusion:</b> We have discovered a number of interesting derivatives that have encouraging cytokine response data and good metabolic stability, with the potential to have a positive impact on ALS either as single agents, or in combination.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Baugh</LastName><ForeName>Simon Dp</ForeName><Initials>SD</Initials><AffiliationInfo><Affiliation>Fox Chase Therapeutics Discovery, Inc., Doylestown, PA 18902, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morrice</LastName><ForeName>Jessica R</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, University of British Columbia, Vancouver, BC, V5Z 3N9, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reitz</LastName><ForeName>Allen B</ForeName><Initials>AB</Initials><AffiliationInfo><Affiliation>Fox Chase Therapeutics Discovery, Inc., Doylestown, PA 18902, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shaw</LastName><ForeName>Christopher A</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, University of British Columbia, Vancouver, BC, V5Z 3N9, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gregory-Evans</LastName><ForeName>Cheryl Y</ForeName><Initials>CY</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, University of British Columbia, Vancouver, BC, V5Z 3N9, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Future Med Chem</MedlineTA><NlmUniqueID>101511162</NlmUniqueID><ISSNLinking>1756-8919</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>2880D3468G</RegistryNumber><NameOfSubstance UI="D007978">Levamisole</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>C8M7RFE4NO</RegistryNumber><NameOfSubstance UI="D013773">Tetramisole</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007978" MajorTopicYN="N">Levamisole</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013773" MajorTopicYN="N">Tetramisole</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><OtherAbstract Type="plain-language-summary" Language="eng"><AbstractText><b>Aim:</b> To discover derivatives of the antiparasitic worm drug levamisole, which has been reported to be able to modulate the immune response, as treatments for amyotrophic lateral sclerosis (ALS), which has been suggested to be in part an autoimmune disease. <b>Results:</b> We have synthesized ten analogs of a variation of levamisole, tetramisole, as well as 11&#xa0;analogs on a related system. All of the analogs have been tested for their ability to affect the response of five ALS-relevant immune-modulatory substances (cytokines). <b>Conclusion:</b> We have discovered a number of interesting derivatives that have encouraging cytokine response data and good metabolic stability, with the potential to have a positive impact on ALS either as single agents, or in combination.</AbstractText></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">cytokine response</Keyword><Keyword MajorTopicYN="N">immune modulation</Keyword><Keyword MajorTopicYN="N">levamisole</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>18</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>12</Day><Hour>7</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>12</Day><Hour>5</Hour><Minute>43</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37170865</ArticleId><ArticleId IdType="doi">10.4155/fmc-2023-0028</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>